Literature DB >> 20818327

Therapeutic targeting of the prostate cancer microenvironment.

Maria Karlou1, Vassiliki Tzelepi, Eleni Efstathiou.   

Abstract

Solid tumors can be thought of as multicellular 'organs' that consist of a variety of cells as well as a scaffold of noncellular matrix. Stromal-epithelial crosstalk is integral to prostate cancer progression and metastasis, and androgen signaling is an important component of this crosstalk at both the primary and metastatic sites. Intratumoral production of androgen is an important mechanism of castration resistance and has been the focus of novel therapeutic approaches with promising results. Various other pathways are important for stromal-epithelial crosstalk and represent attractive candidate therapeutic targets. Hedgehog signaling has been associated with tumor progression, growth and survival, while Src family kinases have been implicated in tumor progression and in regulation of cancer cell migration. Fibroblast growth factors and transforming growth factor beta signaling regulate cell proliferation, apoptosis and angiogenesis in the prostate cancer microenvironment. Integrins mediate communication between the cell and the extracellular matrix, enhancing growth, migration, invasion and metastasis of cancer cells. The contribution of stromal-epithelial crosstalk to prostate cancer initiation and progression provides the impetus for combinatorial microenvironment-targeting strategies.

Entities:  

Mesh:

Year:  2010        PMID: 20818327     DOI: 10.1038/nrurol.2010.134

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  190 in total

1.  Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells.

Authors:  J Gao; J T Arnold; J T Isaacs
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

2.  Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.

Authors:  Giuseppe Di Lorenzo; William D Figg; Sophie D Fossa; Vincenzo Mirone; Riccardo Autorino; Nicola Longo; Ciro Imbimbo; Sisto Perdonà; Antonio Giordano; Mario Giuliano; Roberto Labianca; Sabino De Placido
Journal:  Eur Urol       Date:  2008-02-05       Impact factor: 20.096

3.  Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model.

Authors:  Kristen Bisanz; Jie Yu; Magnus Edlund; Bill Spohn; Mien-Chie Hung; Leland W K Chung; Chia-Ling Hsieh
Journal:  Mol Ther       Date:  2005-10       Impact factor: 11.454

4.  Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.

Authors:  Matthias Lauth; Asa Bergström; Takashi Shimokawa; Rune Toftgård
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-09       Impact factor: 11.205

5.  A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions.

Authors:  Kumiko Maruyama-Takahashi; Naoki Shimada; Teruyoshi Imada; Yoshimi Maekawa-Tokuda; Toshihiko Ishii; Jun Ouchi; Hideaki Kusaka; Hiromasa Miyaji; Shiro Akinaga; Akira Tanaka; Kenya Shitara
Journal:  Prostate       Date:  2008-05-01       Impact factor: 4.104

6.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

7.  Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.

Authors:  X Li; V Placencio; J M Iturregui; C Uwamariya; A-R Sharif-Afshar; T Koyama; S W Hayward; N A Bhowmick
Journal:  Oncogene       Date:  2008-08-25       Impact factor: 9.867

8.  A paracrine requirement for hedgehog signalling in cancer.

Authors:  Robert L Yauch; Stephen E Gould; Suzie J Scales; Tracy Tang; Hua Tian; Christina P Ahn; Derek Marshall; Ling Fu; Thomas Januario; Dara Kallop; Michelle Nannini-Pepe; Karen Kotkow; James C Marsters; Lee L Rubin; Frederic J de Sauvage
Journal:  Nature       Date:  2008-08-27       Impact factor: 49.962

9.  Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases.

Authors:  Jeffrey A Nemeth; Michael L Cher; Zhao Zhou; Chadwick Mullins; Sunita Bhagat; Mohit Trikha
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

10.  Indian hedgehog coordinates endochondral bone growth and morphogenesis via parathyroid hormone related-protein-dependent and -independent pathways.

Authors:  S J Karp; E Schipani; B St-Jacques; J Hunzelman; H Kronenberg; A P McMahon
Journal:  Development       Date:  2000-02       Impact factor: 6.868

View more
  51 in total

Review 1.  Unravelling the complexity of metastasis - molecular understanding and targeted therapies.

Authors:  Nilay Sethi; Yibin Kang
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

Review 2.  Novel therapies for metastatic castrate-resistant prostate cancer.

Authors:  Farshid Dayyani; Gary E Gallick; Christopher J Logothetis; Paul G Corn
Journal:  J Natl Cancer Inst       Date:  2011-09-13       Impact factor: 13.506

Review 3.  Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Med       Date:  2011-05-20       Impact factor: 6.354

Review 4.  Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate.

Authors:  Alejandro S Godoy; Ivy Chung; Viviana P Montecinos; Ralph Buttyan; Candace S Johnson; Gary J Smith
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-04-02       Impact factor: 4.310

5.  Androgen receptors expressed by prostatic stromal cells obtained from younger versus older males exhibit opposite roles in prostate cancer progression.

Authors:  You-Yi Lu; Bo Jiang; Fu-Jun Zhao; Di Cui; Qi Jiang; Jun-Jie Yu; En-Hui Li; Xiao-Hai Wang; Bang-Min Han; Shu-Jie Xia
Journal:  Asian J Androl       Date:  2013-06-24       Impact factor: 3.285

6.  Role of proprotein convertases in prostate cancer progression.

Authors:  Frédéric Couture; François D'Anjou; Roxane Desjardins; François Boudreau; Robert Day
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

7.  Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells.

Authors:  Juan Wen; Yuan Zhao; Jinghe Li; Chunyan Weng; Jingjing Cai; Kan Yang; Hong Yuan; Julianne Imperato-McGinley; Yuan-Shan Zhu
Journal:  Prostate       Date:  2013-02-19       Impact factor: 4.104

8.  Identification of microenvironment related potential biomarkers of biochemical recurrence at 3 years after prostatectomy in prostate adenocarcinoma.

Authors:  Xiaoru Sun; Lu Wang; Hongkai Li; Chuandi Jin; Yuanyuan Yu; Lei Hou; Xinhui Liu; Yifan Yu; Ran Yan; Fuzhong Xue
Journal:  Aging (Albany NY)       Date:  2021-06-16       Impact factor: 5.682

9.  A microchip platform for interrogating tumor-macrophage paracrine signaling at the single-cell level.

Authors:  Meltem Elitas; Kara Brower; Yao Lu; Jonathan J Chen; Rong Fan
Journal:  Lab Chip       Date:  2014-07-24       Impact factor: 6.799

10.  New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells.

Authors:  Soo Ok Lee; Zhifang Ma; Chiuan-Ren Yeh; Jie Luo; Tzu-Hua Lin; Kuo-Pao Lai; Shinichi Yamashita; Liang Liang; Jing Tian; Lei Li; Qi Jiang; Chiung-Kuei Huang; Yuanjie Niu; Shuyuan Yeh; Chawnshang Chang
Journal:  J Mol Cell Biol       Date:  2012-07-24       Impact factor: 6.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.